1093959-24-0

Basic information

• Product Name: C₅₇H₆₉NO₁₇Si
• Synonyms: C₅₇H₆₉NO₁₇Si
• CAS NO: 1093959-24-0
• Molecular Weight: 1068.26
• Mol File: 1093959-24-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₅₇H₆₉NO₁₇Si(CAS DataBase Reference)
• NIST Chemistry Reference: C₅₇H₆₉NO₁₇Si(1093959-24-0)
• EPA Substance Registry System: C₅₇H₆₉NO₁₇Si(1093959-24-0)

Safety Data

• Hazardous Substances Data: 1093959-24-0(Hazardous Substances Data)

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 33069-62-4 taxol 
• 108-30-5 succinic acid anhydride 
• 114655-02-6 2'-O-(tert-butyldimethylsilyl)paclitaxel 

Downstream Products

• 1221127-66-7 C₂'-TBS-C₇-succinyl-paclitaxel-phe-phe-arg chloromethyl ketone 

Relevant articles and documents

Water-soluble anti-tumor compounds

The invention relates to a water-soluble antitumor compound represented by the formula (I), and further relates to a preparation method of the compound and an application of the compound in preparation of antitumor drugs. Stable prodrug with a good water

Paclitaxel succinate analogs: Anionic and amide introduction as a strategy to impart blood-brain barrier permeability

A focused library of TX-67 (C10 hemi-succinate) analogs has been prepared, including C7 regioisomers, esters, amides, and one-carbon homologs. These were prepared to investigate whether the lack of TX-67 interaction with P-glycoprotein (Pgp) is due to the presence of the carboxylic acid moiety and whether this phenomenon was restricted to C10 analogs. Tubulin stabilization ability, cytotoxicity, and Pgp interactions were evaluated. All carboxylic acid analogs and several of the amides had no apparent interactions with Pgp at the concentrations used, whereas the ester variants displayed characteristics of Pgp substrates. Furthermore, it was demonstrated that hydrogen-bonding properties were significant with respect to Pgp interactions. Calculations of log D and cross-sectional areas revealed that these analogs are predicted to partition into the membrane and can compete for Pgp binding sites. The anionic and amide introduction strategy may allow for delivery of paclitaxel into the CNS and may be a potential approach for the delivery of other, structurally complex and lipophilic non-CNS permeable drugs.